RefleXion Medical's biology-guided radiotherapy (BgRT) has received a breakthrough device designation from the U.S. Food and Drug Administration for use in treating lung tumors.
The company envisages that with its technology, injected radiotracers produce active signals to guide delivery of treatment to each tumor present. In comparison, it is possible to reach only one to three tumors with available radiation techniques, RefleXion said.
Tumors in the lung are the most common cause of cancer-related death in the U.S. and the most common site of metastases.
